Yang Xiang to Poly(ADP-ribose) Polymerase Inhibitors
This is a "connection" page, showing publications Yang Xiang has written about Poly(ADP-ribose) Polymerase Inhibitors.
Connection Strength
1.107
-
Du M, Peng P, Cao D, Cheng N, Yao L, Sun Y, Li J, Zhang H, Lou G, Tang J, Wang D, Wang Y, Zhang G, Xiang Y. Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study. J Ovarian Res. 2026 Jan 26; 19(1).
Score: 0.937
-
Zheng H, Gao Y, Guo H, Li L, Li Q, Cui H, Lin A, Sun L, Hu Y, Kang S, Duan W, Pan L, Wang S, Yang Y, Li Y, Kong W, Xiang Y, Tian X, Ling B, Ha C, Bai W. Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. Mol Cancer Ther. 2021 09; 20(9):1735-1742.
Score: 0.170